Drug Approval | September 03, 2024
Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The company has received five final approvals
Furthering cell therapy ambition across oncology and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
